Key result
Milrinone administered as an adjunct to inhaled nitric oxide in neonates with persistent pulmonary hypertension is the focus of this pilot randomized controlled trial protocol, which aims to evaluate feasibility and time spent on respiratory support.
Why the study?
Does intravenous milrinone reduce the time spent on inhaled nitric oxide and invasive ventilation in neonates with persistent pulmonary hypertension of the newborn?
RCT (n=20)
Double-blind
1:1
Yes
Does intravenous milrinone reduce the time spent on inhaled nitric oxide and invasive ventilation in neonates with persistent pulmonary hypertension of the newborn?
This pilot study protocol outlines a randomized controlled trial to assess the feasibility and efficacy of milrinone in reducing the duration of inhaled nitric oxide therapy in neonates with persistent pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
Pilot RCT protocol tests milrinone adjunct to iNO in neonatal PPHN; leaves open impact on respiratory support duration.
Persistent pulmonary hypertension of the newborn (PPHN) is a relatively common condition which results in a mortality of up to 33%. Up to 40% of infants treated with nitric oxide (iNO) either have a transient response or fail to demonstrate an improvement in oxygenation. Milrinone, a selective phosphodiesterase 3 (PDE3) inhibitor with inotropic and lusitropic properties may have potential benefit in PPHN. This pilot study was developed to assess the impact of milrinone administration on time spent on iNO in infants with PPHN. This is a multicentre, randomized, double-blind, two arm pilot study, with a balanced (1:1) allocation of 20 infants. In this pilot study, we hypothesise that infants ≥34 weeks gestation and ≥ 2000 g with a clinical and echocardiography diagnosis of PPHN, intravenous milrinone used in conjunction with iNO will result in a reduction in the time spent on iNO. In addition, we hypothesise that milrinone treatment will lead to an improvement in myocardial performance and global hemodynamics when compared to iNO alone. We will also compare the rate of adverse events associated with the milrinone, and the pre-discharge outcomes of both groups. The purpose of this pilot study is to assess the feasibility of performing the trial and to obtain preliminary data to calculate a sample size for a definitive multi-centre trial of milrinone therapy in PPHN. Trial registration: www.isrctn.com ; ISRCTN:12949496 ; EudraCT Number:2014–002988-16.
No takes yet. Share an insight, caveat, or question.
El‐Khuffash et al. (2018) conducted an RCT in Persistent pulmonary hypertension of the newborn (PPHN) (n=20). Milrinone vs. Placebo (normal saline) was evaluated on Time on inhaled nitric oxide (iNO) and time on invasive ventilation. Milrinone administered as an adjunct to inhaled nitric oxide in neonates with persistent pulmonary hypertension is the focus of this pilot randomized controlled trial protocol, which aims to evaluate feasibility and time spent on respiratory support.
Synapse has enriched 10 related papers. Consider them for comparative context: